Marker Therapeutics, Inc.

Monthly Archives: February 2016

TapImmune Receives Notice of Allowance on U.S. Patent Claims for PolyStart – Next-Generation T-Cell Vaccine

Proprietary DNA Expression Vector Technology Developed at TapImmune’s Laboratories PolyStart to Move into Clinical Trials and Expand TapImmune‘s Development Pipeline TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment of cancer, including metastatic cancer, announced today that it has received a Notice of Allowance from the U.S.
Read More

TapImmune Sponsors 26.2 With DONNA Marathon for Breast Cancer Research and Care

https://www.markertherapeutics.com/wp-content/uploads/2016/02/Donna-Foundation_295x166.jpg Events & Marathon to take place in Jacksonville, Florida on February 12-14, 2016 JACKSONVILLE, FLORIDA, February 10, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer &
Read More

TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer

TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today that the U.S.
Read More